Bill
HF 4852
Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.
2025-2026 Regular Session
Introduced by Robert Bierman and 1 co-sponsor
HF 4852 strengthens transparency and public input in Minnesota’s formulary process, expanding MRDAC input on orphan drugs and requiring open, publicly disclosed decisions.
Introduction and first reading, referred to Health Finance and Policy